{"id":"https://genegraph.clinicalgenome.org/r/4a6e7148-d1ea-4b7b-ae4e-1a3aec8117e4v1.0","type":"EvidenceStrengthAssertion","dc:description":"*CFAP410*, previously *C21orf2*, was first reported in relation to amyotrophic lateral sclerosis (ALS) in 2016 (van Rheenen et al., PMID: 27455348). *CFAP410* encodes cilia-and flagella-associated protein 410 and has a role in ciliogenesis and DNA damage repair. *CFAP410* has also been associated with autosomal recessive retinal dystrophy with macular staphyloma and autosomal recessive axial spondylometaphyseal dysplasia. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found a difference in inheritance pattern and phenotypic variability among these diseases. Therefore, the following disease entities have been split into separate disease entities: semi-dominant ALS (OMIM: 105400), autosomal recessive retinal dystrophy with macular staphyloma (OMIM: 617547) and autosomal recessive axial spondylometaphyseal dysplasia (OMIM: 602271). The association between *CFAP410* and ALS was first established in a genome-wide variant case-control analysis that identified an association between a risk variant in the gene, described as rs75087725 (Val58Leu), and the phenotype based on the genome sequencing of 12,577 ALS cases and 23,475 controls (van Rheenen et al., PMID:27455348). Per criteria set by the ALS GCEP, the missense variant found in this study is outside the established gnomAD minor allele frequency cutoffs (<0.00005) and, while is unlikely to be a main cause of disease, reached a level of significance. To date, no causal variants in *CFAP410* have been documented in ALS patients in the literature. The mechanism of pathogenicity is currently unclear. This gene-disease association is supported by experimental evidence describing expression of* CFAP410* in neuronal tissues, physical interaction with known ALS associated gene *NEK1* and functional alterations in non-patient cells (PMIDs: 36131690, 26290490, and 32891887). In summary, there is limited evidence to support this gene-disease relationship. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. It is important to understand that in the clinical diagnostic setting the identification of variants of uncertain significance may be common and variant interpretation must be completed with caution. This classification was approved by the ClinGen ALS GCEP on December 12, 2023.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/4a6e7148-d1ea-4b7b-ae4e-1a3aec8117e4","GCISnapshot":"https://genegraph.clinicalgenome.org/r/bde7edf1-ccfa-443e-a917-cf3d2dd9cba6","calculatedEvidenceStrength":"Limited","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/bde7edf1-ccfa-443e-a917-cf3d2dd9cba6_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2023-12-12T18:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/bde7edf1-ccfa-443e-a917-cf3d2dd9cba6_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2024-06-05T03:17:17.020Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bde7edf1-ccfa-443e-a917-cf3d2dd9cba6_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bde7edf1-ccfa-443e-a917-cf3d2dd9cba6_cc_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7513e2c-5821-4fc1-8c6e-c89429de3409","type":"EvidenceLine","dc:description":"This variant is really common","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7513e2c-5821-4fc1-8c6e-c89429de3409_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27455348","rdfs:label":"Risk Variant analysis","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/193545e5-7ae4-4524-b7c2-279d0c11989c","type":"Cohort","allGenotypedSequenced":12577,"alleleFrequency":0.01987755426572315,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7513e2c-5821-4fc1-8c6e-c89429de3409_cc_evidence_item"}],"numWithVariant":250,"relatedCondition":{"id":"obo:MONDO_0004976"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/68c92421-97e0-4cf7-9c2d-0634737eb539","type":"Cohort","allGenotypedSequenced":23475,"alleleFrequency":0.01448349307774228,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7513e2c-5821-4fc1-8c6e-c89429de3409_cc_evidence_item"}],"numWithVariant":340},"lowerConfidenceLimit":1.28,"method":{"id":"cg:SingleVariantAnalysis"},"pValue":2.65E-9,"statisticalSignificanceType":"","statisticalSignificanceValue":1.45,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":1.65}],"specifiedBy":"GeneValidityCaseControlSingleVariantAnalysisCriteria","strengthScore":3.5}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":3.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":3.5},{"id":"https://genegraph.clinicalgenome.org/r/bde7edf1-ccfa-443e-a917-cf3d2dd9cba6_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bde7edf1-ccfa-443e-a917-cf3d2dd9cba6_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/03348138-ff97-4434-bc6b-ee7a019d7f9b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3a66df5b-ea02-46ad-8fec-2257a4a720e8","type":"FunctionalAlteration","dc:description":"FBXO3 bound to C21ORF2(WT), whereas FBXO3 did not bind to C21ORF2(V58L) and the mutant protein was not ubiquitylated in HEK293T cells, suggesting that FBXO3 is the only ubiquitin ligase for C21ORF2 and that the ALS-related V58L mutation prevents the ubiquitylation of C21ORF2. Given that SCFFBXO3 targets C21ORF2 for proteasomal degradation, C21ORF2(V58L) might be expected to be more stable than the WT protein.  The percentage amount of C21ORF2(V58L) remaining during the time course was significantly greater than that of C21ORF2(WT), indicating that C21ORF2(V58L) is indeed more stable than is C21ORF2(WT) as a result of not being a substrate of SCFFBXO3.\n\n The measured average length of neurites formed by the GFP-positive cells for VLKI iMNs was significantly shorter than that for iMNs differentiated from the parental ESCs ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32891887","rdfs:label":"CFAP410 Hyperphosphorylation"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/bde7edf1-ccfa-443e-a917-cf3d2dd9cba6_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cfb2a7ec-6965-465b-afdb-4ffd2e98e0c1","type":"EvidenceLine","dc:description":"DNA damage repair is not specific to ALS","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/21ac2ad5-6305-4fdd-843c-525be664f08a","type":"Finding","dc:description":"Figure 4","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26290490","rdfs:label":"DNA Damage Repair","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/2550dd4b-b905-446e-a2af-5f65692d8eee","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ece0265c-b5c2-490f-b4b5-ede7cc85a972","type":"Finding","dc:description":"Numerous variants in NEK1 have been implicated a cause of ALS, this disease-gene relationship has been curated and classed as \"definitive\" by the ClinGen ALS GCEP. HA-NEK1 was transiently transfected into HeLa cells. Forty-eight hours after transfection, the cells were collected for co-IP analysis with the anti-HA antibody. C21ORF2 in the immune complex was detected by western blot analysis with anti-C21ORF2 antibody. \n\nBoth genes are shown to be involved in DNA repair and was hypothesized they may work together. This is shown by NEK1 being overexpressed in C21ORF2-depleted cells, and the ability of these cells to repair DSBs was examined. By the analysis of Î³H2AX foci formation, overexpression of NEK1 was found to significantly rescue DNA damage repair defects in C21ORF2-knockdown cells ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26290490","rdfs:label":"NEK1  Interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/93576071-f502-47dd-8dd5-408e107f938b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b71eb8d1-96de-4c88-a5f8-4bc10d161a35","type":"Finding","dc:description":"RNA-seq data from tissues from the Target ALS cohort. Authors compared different isoforms of CFAP410 against healthy controls to see if there is a correlation in ALS and expressed VNTR isoforms. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36131690","rdfs:label":"VNTR CNS expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.25}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1.75}],"evidenceStrength":"Limited","sequence":8351,"specifiedBy":"GeneValidityCriteria10","strengthScore":5.25,"subject":{"id":"https://genegraph.clinicalgenome.org/r/-Pdm_RMTzc4","type":"GeneValidityProposition","disease":"obo:MONDO_0004976","gene":"hgnc:1260","modeOfInheritance":"obo:HP_0032113"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_bde7edf1-ccfa-443e-a917-cf3d2dd9cba6-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}